DOCSLIB.ORG

Zinc Supplementation in Children and Adolescents with Acute Leukemia

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Zinc Supplementation in Children and Adolescents with Acute Leukemia European Journal of Clinical Nutrition (2013) 67, 1056–1059 & 2013 Macmillan Publishers Limited All rights reserved 0954-3007/13 www.nature.com/ejcn ORIGINAL ARTICLE Zinc supplementation in children and adolescents with acute leukemia LZZ Consolo, P Melnikov, FZ Coˆ nsolo, VA Nascimento and JCDV Pontes BACKGROUND/OBJECTIVES: Zinc is known as an essential micronutrient for human health because of its structural and biochemical functions, influencing growth and affecting multiple aspects of the immune system. Zinc has been extensively studied in neoplastic processes but its role in children with leukemia still remains to be elucidated in several aspects. The aim of this study was to evaluate the effects of oral zinc supplementation on weight gain and infectious episodes in children and adolescents with acute leukemia. SUBJECTS/METHODS: This study included 38 patients, and was carried out as a randomized, double-blind, placebo-controlled investigation. The dosage of plasma zinc levels and the evaluation of nutritional status were performed during a period of 60 days. Zinc was supplemented orally, 2 mg/kg/day, in the form of amino acid salt. RESULTS: The results showed that plasma zinc concentrations did not increase significantly with the addition of the micronutrient. However, from a clinical point of view, it has become evident that supplementary zinc exerts a positive effect on nutritional status as positive weight gain. Moreover, the number of infection episodes was significantly reduced, possibly because of the immune stimuli. CONCLUSIONS: In conclusion, zinc supplementation can prevent some of the chemotherapy adverse effects in children with leukemia, improving their quality of life. European Journal of Clinical Nutrition (2013) 67, 1056–1059; doi:10.1038/ejcn.2013.146; published online 21 August 2013 Keywords: zinc supplementation; leukemia; children; adolescents INTRODUCTION SUBJECTS AND METHODS Zinc is known as an essential micronutrient for human health A double-blind, placebo-controlled study was conducted in children within because of its structural and biochemical functions at cellular the age interval of 1–18 years, of both genders, who had a previously and subcellular levels, influencing growth and affecting multiple established clinical and laboratorial diagnosis either of lymphocytic or aspects of the immune system.1–3 It is known that even a marginal myeloid leukemia. They were undergoing chemotherapy, according to the established protocols for this disease, at the Regional Hospital ‘Rosa Maria zinc deficiency may be accompanied by an imbalance of T helper Pedrossian’, in Campo Grande, MS, Brazil, from March 2010 through type 1 and 2 cells. The beneficial effects of its supplementation in February 2012. The following exclusion criteria were applied in order to children in the management of infantile diarrhea, acute respiratory select the participants: acute infectious disease, renal failure, postsurgery infections and pneumonia are evidenced by decreased morbidity status or usage of any zinc-containing drug. An informed written consent and mortality.4,5 was obtained from the parents or person responsible before enrollment. Zinc supplementation manifests significant positive effects The project has been duly approved by the Ethical Committee of Federal on linear growth, especially when administered alone, and hence University of Mato Grosso do Sul. it was strongly recommended in the National Health Service Data on anthropometric parameters, nutritional status and plasma zinc 6 concentration were collected at the beginning of supplementation (T ), 30 strategies in order to reduce stunting in children o5 years of age. 0 days later (T30) and 60 days later (T60). The classification of the nutritional It was logical to believe that zinc might also be useful in status was based on the body weight, stature, arm circumference-for-age patients undergoing chemotherapy for acute leukemia and its and triceps skinfold-for-age.9–11 consecutive complications. So far, at least two zinc compounds In addition, xerostomy, taste dysfunction, nausea and vomiting were were shown to have the activity of their own in acute myeloid registered weekly for a period of 60 days. These data were taken from leukemia. The former is pyrithione zinc, which appears to possess medical records or provided by parents. As for the episodes of mucositis or the potential to directly suppress neoplastic activity,7 and clinically diagnosed infections, these were referred up to a broader period the latter is zinc ascorbate, proposed to diminish deleterious of 120 days (T120). effects of chemotherapy in children.8 As for the chemotherapy A total of 38 patients were randomized into two groups: one was given complications, infections and mucosal damage can be mentioned. orally placebo syrup containing no zinc (group A, n ¼ 18) and the other group (group B, n ¼ 20) received syrup containing zinc in the form of a The purpose of the present investigation was to evaluate the chelate solution (10 mg/ml). In total, group B was given 2 mg/kg/day of effects of oral zinc supplementation on weight gain and infectious zinc (maximum 60 mg/day) in two divided doses. The packages were episodes in children and adolescents with acute leukemia. Special identical in color, taste, odor and appearance. Both syrups were attention was given to the simultaneous nutritional assessment of manufactured by a single pharmacy. Zinc chelate was purchased from the patients. the Pharmanostra Laboratory (Ana´polis, Brazil). The bottles were randomly Federal University of Mato Grosso do Sul, Campo Grande, Mato Grosso do Sul, Brazil. Correspondence: Professor LZZ Consolo, Federal University of Mato Grosso do Sul, Rua Alexandre 378, Giocondo Orsi, Campo Grande, Mato Grosso do Sul CEP-79022-080, Brazil. E-mail: [email protected] Received 6 March 2013; revised 8 July 2013; accepted 11 July 2013; published online 21 August 2013 Zinc supplementation in leukemia LZZ Consolo et al 1057 labeled as A for placebo group and B for zinc group by a pharmacist not involved in the study. Neither the researchers nor the participants had any Table 1. Initial assessment (%) of nutritional status previous knowledge regarding the content of the bottles. All the children who participated in the study took the syrup for 60 days. Nutritional status All participants Group A Group B For plasma zinc analysis, blood samples were collected in polypropylene Mild malnutrition 18.4 (n 7) 16.7 (n 3) 20 (n 4) syringes and immediately transferred to vacuum tubes free of trace ¼ ¼ ¼ Nutritional risk 10.5 (n 4) 5.6 (n 1) 15 (n 3) elements (BD Vacutainer Systems–Becton, Dickinson and Company, ¼ ¼ ¼ Normal nutrition 52.6 (n 20) 61.1 (n 11) 45 (n 9) Sa˜o Paulo, Brazil). The plasma was separated by centrifugation and stored ¼ ¼ ¼ Overweight risk 5.3 (n ¼ 2) 0 10 (n ¼ 2) at À 18 1C for later analytical determinations. Overweight 10.5 (n 4) 11.1 (n 2) 10 (n 2) All materials, plastic or glass were previously treated for decontamina- ¼ ¼ ¼ Obesity 2.6 (n 1) 5.6 (n 1) 0 tion of any possible contaminant. The calibration curves were constructed ¼ ¼ Total 100 (n 38) 100 (n 18) 100 (n 20) using four different zinc concentrations with values in the range of ¼ ¼ ¼ 0.25–2.0 mg/l. Atomic absorption analyses for plasma zinc were performed with a PerkinElmer AA100 spectrometer (Waltham, MA, USA). The statistical analysis was carried out using mean±s.d., Student’s t-test, Pearson’s correlation, Fisher’s test, w2 test and analysis of variance. Data Table 2. Ranges of zinc concentrations (mg/l) and their averages at were analyzed using BioEstat, Version 5.0 statistical package (Minneapolis, different periods MN, USA). The value of ‘P’ adopted was p0.05. Group T0 T30 T60 RESULTS Group A 0.22–1.45 0.6–1.55 0.75–1.30 (mean±s.d.) 0.99±0.08 1.0±0.07 0.99±0.04 In group A, 83.3% (n ¼ 15) had acute lymphocytic leukemia and Group B 0.6–1.9 0.8–1.9 0.6–1.55 16.7% (n ¼ 3) had acute myelocytic leukemia. In group B, 80% (mean±s.d.) 1.0±0.07 1.2±0.08 1.0±0.07 (n ¼ 16) had acute lymphocytic leukemia and 20% (n ¼ 4) had acute myelocytic leukemia. No difference was observed according Abbreviations: T0, time at the beginning of supplementation; T30, time after 30 days; T , time after 60 days. to diagnosis between the two groups (P ¼ 0.937). There were 53% 60 (n ¼ 20) male and 47% (n ¼ 18) female patients. The mean age in both groups was 9.9±5.5 years. There were no significant differences between both groups according to age (P ¼ 0.328), Zinc has been extensively studied in neoplastic processes but its gender (P ¼ 0.213), weight (P ¼ 0.609) and height (P ¼ 0.38) at T0. role in children with leukemia still remains to be elucidated in Table 1 shows the initial assessment of nutritional status of the several aspects. As a matter of fact, this study showed an participants. This status of the patients was found inadequate in improvement in the outcome of children with zinc supplementation, 28.9% of diagnosis. A significant difference was observed between regarding weight and episodes of infection. the groups according to weight gain at T30 and T60. The weight A mild to severe nutritional depletion can be present in gain of 2000 g for B group was higher than that observed B11–50% of children with leukemia before treatment, for group A. For group A, the weight gain was 100 g, showing a thus influencing the course and prospects for patients’ significant difference (P ¼ 0.032). As for height values, improvement.11–15 This large variation is because of several no significant differences were observed between the groups factors such as socioeconomic status and educational and cultural A and B.
Load more

Recommended publications
  • Word Equations
    Chemical misconceptions 33 Word equations Target level These materials are designed for use with 11–14 year old students who have been taught to use word equations. The materials will also be useful for 14–16 year olds students who need to revisit this topic. Topic Using word equations to represent chemical reactions. Rationale Many students find it difficult to write word equations, which require an appreciation of the nature of chemical change (including conservation of matter), and familiarity with chemical names and the patterns of common reaction types. These materials provide probes for exploring whether students can complete word equations, and a set of practice exercises. These ideas are discussed in Chapter 9 of the Teachers’ notes. In the pilot teachers judged the materials ‘excellent’, ‘very useful’ and ‘helpful for revision’. Some teachers found the responses of some of their pupils to be ‘disappointing’ (or even ‘shocking’). The probes were thought to provide an interesting ‘look into [students’] minds’ and to lead to useful classroom discussion. Although teachers found it useful that students were asked to give reasons for their answers, some of the students did not like having to try to explain their reasons. (Some teachers may wish to ask students to just complete the equations in the probes, and to leave the spaces for making notes when going through the answers.) Students were reported to find the materials helpful and easy to follow, and were considered to have greater understanding afterwards. Instructions These materials may either be used with students who should have mastered word equations as a pre-test (to identify students needing practice), a remedial exercise, and a post-test; or as end-of-topic review material with students meeting word equations for the first time.
    [Show full text]
  • Zinc Sulphate
    RISK ASSESSMENT REPORT ZINC SULPHATE CAS-No.: 7733-02-0 EINECS-No.: 231-793-3 GENERAL NOTE This document contains: - part I Environment (pages 41) - part II Human Health (pages 130) R076_0805_env RISK ASSESSMENT ZINC SULPHATE CAS-No.: 7733-02-0 EINECS-No.: 231-793-3 Final report, May 2008 PART 1 Environment Rapporteur for the risk evaluation of zinc sulphate is the Ministry of Housing, Spatial Planning and the Environment (VROM) in consultation with the Ministry of Social Affairs and Employment (SZW) and the Ministry of Public Health, Welfare and Sport (VWS). Responsible for the risk evaluation and subsequently for the contents of this report is the rapporteur. The scientific work on this report has been prepared by the Netherlands Organization for Applied Scientific Research (TNO) and the National Institute of Public Health and Environment (RIVM), by order of the rapporteur. Contact point: Bureau Reach P.O. Box 1 3720 BA Bilthoven The Netherlands R076_0805_env PREFACE For zinc metal (CAS No. 7440-66-6), zinc distearate (CAS No. 557-05-1 / 91051-01-3), zinc oxide (CAS No.1314-13-2), zinc chloride (CAS No.7646-85-7), zinc sulphate (CAS No.7733- 02-0) and trizinc bis(orthophosphate) (CAS No.7779-90-0) risk assessments were carried out within the framework of EU Existing Chemicals Regulation 793/93. For each compound a separate report has been prepared. It should be noted, however, that the risk assessment on zinc metal contains specific sections (as well in the exposure part as in the effect part) that are relevant for the other zinc compounds as well.
    [Show full text]
  • US EPA Inert (Other) Pesticide Ingredients
    U.S. Environmental Protection Agency Office of Pesticide Programs List of Inert Pesticide Ingredients List 3 - Inerts of unknown toxicity - By Chemical Name UpdatedAugust 2004 Inert Ingredients Ordered Alphabetically by Chemical Name - List 3 Updated August 2004 CAS PREFIX NAME List No. 6798-76-1 Abietic acid, zinc salt 3 14351-66-7 Abietic acids, sodium salts 3 123-86-4 Acetic acid, butyl ester 3 108419-35-8 Acetic acid, C11-14 branched, alkyl ester 3 90438-79-2 Acetic acid, C6-8-branched alkyl esters 3 108419-32-5 Acetic acid, C7-9 branched, alkyl ester C8-rich 3 2016-56-0 Acetic acid, dodecylamine salt 3 110-19-0 Acetic acid, isobutyl ester 3 141-97-9 Acetoacetic acid, ethyl ester 3 93-08-3 2'- Acetonaphthone 3 67-64-1 Acetone 3 828-00-2 6- Acetoxy-2,4-dimethyl-m-dioxane 3 32388-55-9 Acetyl cedrene 3 1506-02-1 6- Acetyl-1,1,2,4,4,7-hexamethyl tetralin 3 21145-77-7 Acetyl-1,1,3,4,4,6-hexamethyltetralin 3 61788-48-5 Acetylated lanolin 3 74-86-2 Acetylene 3 141754-64-5 Acrylic acid, isopropanol telomer, ammonium salt 3 25136-75-8 Acrylic acid, polymer with acrylamide and diallyldimethylam 3 25084-90-6 Acrylic acid, t-butyl ester, polymer with ethylene 3 25036-25-3 Acrylonitrile-methyl methacrylate-vinylidene chloride copoly 3 1406-16-2 Activated ergosterol 3 124-04-9 Adipic acid 3 9010-89-3 Adipic acid, polymer with diethylene glycol 3 9002-18-0 Agar 3 61791-56-8 beta- Alanine, N-(2-carboxyethyl)-, N-tallow alkyl derivs., disodium3 14960-06-6 beta- Alanine, N-(2-carboxyethyl)-N-dodecyl-, monosodium salt 3 Alanine, N-coco alkyl derivs.
    [Show full text]
  • 1,399,500. Patented Dec, 6, 1921
    C, R, KUAE PR0 (CESS OF MANUFACT UR | N G | TH 0P 0 N E À PPLICATION FILED AUG, 15, 1921, 1,399,500. Patented Dec, 6, 1921. UNITED STATES PATENT OFFICE. CHEARTES. R. E.U2ELE, OF CLARKDALE, ARIZONA. SLLaLLLLLLL0LLLL GLLLLS LLLLLLLYLLLLLLLY LLLL LLLLLLLLS LLLGLLGGLGLLYS 1,399,500. specification of Tetters Patent, latented Dec. 6, 1921. Application filed August 15, 192i. Serial No. 492,342. ?? ??? ?????? ?? ???? ???????"?, these tanks) in which the crude lithopone Be it known that II, CHARLES R. KUZELL, is allowed to thicken by settling until it is a citizen of the United States, residing at concentrated to a Suitably dense pulp after Clarkdale, in the county of Yavapai and which it is drawn off by a high pressure 60 State of Arizona, have invented certain new pump 2 and discharged through suitable and useful Improvements in Processes of Spray nozzles 3 into a desiccating chamber 4 Manufacturing Lithopone, of which the fol through which the fine snray is carried by lowing is a specification. a current of air admitted to the chamber 4. My invention has relation to improve through a spray head 5 terminating the air 65 ments in the manufacture of lithopone, the Supply conduit 6. The air current and the process of which consists in the novel com finely divided lithopone are thoroughly bination of steps more fully set forth here mixed in the desiccating chamber, the latter inafter. being carried through the chamber by the The object of the present invention is to air current, which dries the lithopone as it 70 15 simplify the present method of manufac is carried through the chamber.
    [Show full text]
  • ZINCI SULFAS ZINC SULFATE Final Text for Addition to the International
    Document QAS/07.194/FINAL February 2008 . ZINCI SULFAS ZINC SULFATE Zinc sulfate monohydrate Zinc sulfate heptahydrate Final text for addition to The International Pharmacopoeia This monograph was adopted at the Forty-second WHO Expert Committee on Specifications for Pharmaceutical Preparations in October 2007 for addition to the 4 th edition of The International Pharmacopoeia . ZnSO 4,H2O (monohydrate); ZnSO 4,7H2O (heptahydrate) Relative molecular mass. 179.5 (monohydrate); 287.5 (heptahydrate). Chemical name. Zinc sulfate monohydrate; CAS Reg. No. 7446-19-7 (monohydrate). Zinc sulfate heptahydrate; CAS Reg. No. 7446-20-0 (heptahydrate). Description. A white or almost white, crystalline powder, or colourless, transparent crystals. Solubility. Very soluble in water, practically insoluble in ethanol (~750 g/l) TS. Category. Adjunct to oral rehydration salts in( prevention and) treatment of dehydration due to diarrhoea; astringent. Storage. Zinc sulfate should be kept in a well-closed, non-metallic container. Labelling. The designation on the container should state whether the substance is in the monohydrate or heptahydrate form and, where appropriate, that it is suitable for use in the manufacture of parenteral dosage forms. Requirements Definition. Zinc sulfate monohydrate contains not less than 99.0% and not more than 101.0% of ZnSO 4,H2O. Zinc sulfate heptahydrate contains not less than 99.0% and not more than 104.0% of ZnSO 4,7H2O. Document QAS/07.194/FINAL page 2 Identity tests A. Dissolve 0.25 g in 5 ml of water R and add 0.2 ml of sodium hydroxide (400 g/l) TS. A white precipitate is formed. Add a further 2 ml of sodium hydroxide (400 g/l) TS.
    [Show full text]
  • Acute Toxicity of Zinc Sulfate Heptahydrate (Znso4*7H2O) And
    Aquacu nd ltu a r e s e J i o r u e r h n Zeng et al., Fish Aqua J 2018, 9:1 s a i l F Fisheries and Aquaculture Journal DOI: 10.4172/2150-3508.1000240 ISSN: 2150-3508 Research Article Open Access Acute Toxicity of Zinc Sulfate Heptahydrate (ZnSO4*7H2O) and Copper (II) Sulfate Pentahydrate (CuSO4*5H2O) on Freshwater Fish, Percocypris pingi Ling Zeng, Lan Huang, Ming Zhao, Sheng Liu, Zhengjian He, Jupan Feng, Chuanjie Qin and Dengyue Yuan* Department of Aquaculture, College of Life Sciences, Neijiang Normal University, Neijiang, Sichuan, 641100, PR China *Corresponding author: Dengyue Yuan, Department of Aquaculture, College of Life Sciences, Neijiang Normal University, Neijiang, Sichuan, 641100, PR China, Tel: +86(0832) 234-4599; E-mail: [email protected] Received date: February 23, 2018; Accepted date: March 14, 2018; Published date: March 29, 2018 Copyright: © 2018 Yuan D, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract This study was carried out to determine acute toxicity of two heavy metals (zinc and copper) to fingerlings Percocypris pingi by static bioassays. The experimental fish were subjected to a range of concentrations of heavy metals. At different exposure periods (24 h, 48 h, 72 h and 96 h), the mortality rate were separately investigated. The median lethal concentration (LC50) was determined with Probit analysis. The LC50 values of zinc for the Percocypris pingi at 24 h, 48 h, 72 h and 96 h were 3.504 mg/L, 2.933 mg/L, 2.852 mg/L and 2.852 mg/L, respectively.
    [Show full text]
  • C09c - 2020.01
    CPC - C09C - 2020.01 C09C TREATMENT OF INORGANIC MATERIALS, OTHER THAN FIBROUS FILLERS, TO ENHANCE THEIR PIGMENTING OR FILLING PROPERTIES (preparation of inorganic compounds or non-metallic elements C01; treatment of materials specially adapted to enhance their filling properties in mortars, concrete or artificial stone C04B 14/00, C04B 18/00, C04B 20/00); PREPARATION OF CARBON BLACK; {PREPARATION OF INORGANIC MATERIALS WHICH ARE NO SINGLE CHEMICAL COMPOUNDS AND WHICH ARE MAINLY USED AS PIGMENTS OR FILLERS} Definition statement This place covers: The treatment of inorganic compounds other than fibrous fillers, to enhance their pigmenting or filling properties; Preparation of carbon black. Preparation of inorganic materials being no single chemical compounds and used as pigments or fillers. References Limiting references This place does not cover: Treatment by polymerisation onto particle is classified in C08F 292/00. Only treatment by already polymerised agents is classified in C09C. Special rules of classification The following IPC groups are not used in the internal CPC classification scheme. Subject matter covered by these groups is classified in the following CPC groups: IPC group C09C1/68 is covered by CPC group C09K 3/14. Whenever in groups C09C 1/00 - C09C 1/66 the materials consist of a particulate core bearing a coating or any other deposit, classification is done only according to the composition of the core, unless otherwise stated, e.g. C09C 1/0015, C09C 1/0078. Preparations of materials which are no single chemical compounds, mainly comprising ceramic pigments (C09C 1/0009),consisting of solid solutions or polycristalline structures, and compounds defined as composite materials (C09C 1/0081).Preparation and treatment steps are not always easy to distinguish from each other, e.g.
    [Show full text]
  • Zinc Therapy in Dermatology: a Review
    Hindawi Publishing Corporation Dermatology Research and Practice Volume 2014, Article ID 709152, 11 pages http://dx.doi.org/10.1155/2014/709152 Review Article Zinc Therapy in Dermatology: A Review Mrinal Gupta, Vikram K. Mahajan, Karaninder S. Mehta, and Pushpinder S. Chauhan DepartmentofDermatology,Venereology&Leprosy,Dr.R.P.Govt.MedicalCollege,Kangra(Tanda),HimachalPradesh176001,India Correspondence should be addressed to Vikram K. Mahajan; [email protected] Received 1 May 2014; Accepted 23 June 2014; Published 10 July 2014 Academic Editor: Craig G. Burkhart Copyright © 2014 Mrinal Gupta et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Zinc, both in elemental or in its salt forms, has been used as a therapeutic modality for centuries. Topical preparations like zinc oxide, calamine, or zinc pyrithione have been in use as photoprotecting, soothing agents or as active ingredient of antidandruff shampoos. Its use has expanded manifold over the years for a number of dermatological conditions including infections (leishmaniasis, warts), inflammatory dermatoses (acne vulgaris, rosacea), pigmentary disorders (melasma), and neoplasias (basal cell carcinoma). Although the role of oral zinc is well-established in human zinc deficiency syndromes including acrodermatitis enteropathica, it is only in recent years that importance of zinc as a micronutrient essential for infant
    [Show full text]
  • Chemical Reactions. Balance Each Equation. 1. Zinc + Copper (II) Sulfate → Copper + Zinc Sulfate Zn + Cuso4 → Cu + Znso4 2
    Chemical Reactions. Balance Each Equation. 1. zinc + copper (II) sulfate → copper + zinc sulfate Zn + CuSO4 → Cu + ZnSO4 2. potassium chlorate → potassium chloride + oxygen 2KClO3 → 2KCl + 3 O2 3. potassium iodide + lead (II) nitrate → lead (II) iodide + potassium nitrate 2KI + Pb(NO3)2 → PbI2 + 2KNO3 4. iron (III) oxide + carbon → iron + carbon monoxide Fe2O3 + 3C → 2Fe + 3CO 5. iron + water → hydrogen + iron (III) oxide 2Fe + 3H2O → 3H2 + Fe2O3 6. aluminum + sulfuric acid → aluminum sulfate + hydrogen 2Al + 3H2SO4 → Al2(SO4)3 + 3H2 7. magnesium chloride + ammonium nitrate → magnesium nitrate + ammonium chloride MgCl2 + 2NH4NO3 → Mg(NO3)2 + 2NH4Cl 8. mercury (II) oxide → mercury + oxygen 2HgO → 2Hg + O2 9. sodium carbonate + calcium hydroxide → sodium hydroxide + calcium carbonate 2Na2CO3 + Ca(OH)2 → 2NaOH + CaCO3 10. phosphorus + oxygen → phosphorus pentoxide 2P + 5O2 → 2PO5 11. sodium + water → sodium hydroxide + hydrogen 2Na + 2HOH → 2NaOH + H2 12. zinc + sulfuric acid → zinc sulfate + hydrogen Zn + H2SO4 → ZnSO4 + H2 13. calcium oxide + water → calcium hydroxide CaO + H2O → Ca(OH)2 14. iron + copper (I) nitrate → iron (II) nitrate + copper Fe + 2CuNO3 → Fe(NO3)2 + 2Cu 15. potassium oxide + water → potassium hydroxide K2O + H2O → 2KOH 16. ammonium sulfide + lead (II) nitrate → ammonium nitrate + lead (II) sulfide (NH4)2S + Pb(NO3)2 → 2NH4NO3 + PbS 17. mercury (II) hydroxide + phosphoric acid → mercury (II) phosphate + water 3Hg(OH)2 + 2H3PO4 → Hg3(PO4)2 + 6H2O 18. potassium hydroxide + phosphoric acid → potassium phosphate + water 3KOH + H3PO4 → K3PO4 + HOH 19. calcium chloride + nitric acid → calcium nitrate + hydrochloric acid CaCl2 + 2HNO3 → Ca(NO3)2 + 2HCl 20. potassium carbonate + barium chloride → potassium chloride + barium carbonate K2CO3 + BaCl2 → 2KCl + BaCO3 21.
    [Show full text]
  • Wettable Powder Versus Tank-Mix Dithiocarbamates on Potatoes and Tomatoes in Ohio
    RESEARCH CIRCULAR 9 APRIL 11953 WETTABLE POWDER versus TANK-MIX DITHIOCARBAMATES on POTATOES and TOMATOES 1n• OHIO • J. D. WILSON • OHIO AGRICULTURAL EXPERIMENT STATION W 0 0 S T E R, 0 H I 0 CONTENTS * * Introduction .. 3 Preliminary Work 4 Results and Discussion 6 Conclusions ..... 19 Literature Citations . 20 Appendix .... .. 21 WETTABLE POWDER VERSUS TANK-MIX DITHIOCARBAMATES ON POTATOES AND TOMATOES IN OHIO J. D. WILSON INTRODUCTION The dithiocarbamates have now been used as fungicides in Ohio, experimentally or otherwise, for more than 15 years ( 4) . F ermate (ferbam), or ferric dimethyl dithiocarbamate, was the first of these to be used on tomatoes and potatoes, to which it was applied both as spray and dust mixtures prepared from a wettable powder formulation ( 1, 2). Dithane and Parzate have now been tested experimentally for several years both as wettable powders (zineb) and as "tank-mix" formulations of solubilized zinc sulfate plus liquid disodium ethylene bis dithiocarbamate (nabam). There has always been some question as to which type of formulation is capable of giving the best control of such diseases as the early and late blights of potato and tomato ( 10, 12). During the same period, as good or better results were being obtained with a slurry form of zinc dimethyl dithiocarbamate than with the cor­ responding wettable powders known as Zerlate and Methasan (ziram) (16,17,18). The wettable powder formulations of such fungicides as ferbam, ziram, and zineb are prepared by the manufacturer for use in spray and dust applications. The active ingredients of these powder formulations, which are comparatively insoluble and non-wettable, are made wettable by adding wetting and/or conditioning agents.
    [Show full text]
  • Treatment of Pityriasis Versicolour with Topical 15% Zinc Sulfate Solution
    Treatment of Pityriasis Versicolour with Topical 15% Zinc Sulfate Solution Khalifa E. Sharquie Wisam S. Al- Dori MD; PhD. MD; FIBMS. Inas K. Sharquie Adil A. Al– Nuaimy BSc; MSc. MD; DDV; FICMS. Abstract Background: Pityriasis versicolour is a common skin problem of cosmetic importance among young individuals. Many modality of the treatment have been used to control this disease, but often end with relapse. Zinc sulfate had been proven to have antifungal activity invitro study. Still we are searching for a new therapeutic agent like zinc sulfate. Objective: The aim of the present work is to assess the therapeutic effectiveness of topical 15% zinc sulfate solution in treatment of tinea versicolor. Patients& Methods: This single blinded controlled therapeutic trail was carried out in Department of Dermatology and Venereology - Baghdad Teaching Hospital, during the period from May 2004- Sept. 2004. Patients consisted of 60 person (40 males&20 females) and their ages ranged from 15 – 45 years with a mean ± SD of 32 ± 3 years, while the duration of the disease was 2-30 ( 5.18 ± 4.77) months. These patients were enrolled in this study and were divided into two groups:- Group A: Thirty patients (16 males and 14 females) were treated with topical 15% zinc sulfate solution once daily and examine every week for three weeks and followed up for one month without therapy. Mycological and Wood's light examination were performed to establish diagnosis before therapy and repeated every week to asses the response to therapy. Group B: Thirty patients (24 males and 6 females) were treated with distilled water as a placebo treated group and with a similar manner in group A.
    [Show full text]
  • Zinc Sulfate Monohydrate Creation Date 21
    SAFETY DATA SHEET according to Regulation (EC) No 1907/2006 (REACH) as amended Zinc sulfate monohydrate Creation date 21. September 2019 Revision date Version 1.0 SECTION 1: Identification of the substance/mixture and of the company/undertaking 1.1. Product identifier Zinc sulfate monohydrate Substance / mixture substance Chemical name zinc sulphate (hydrous) (mono-, hexa- and hepta hydrate) CAS number 7446-19-7 Index number 030-006-00-9 EC (EINECS) number 231-793-3 1.2. Relevant identified uses of the substance or mixture and uses advised against Substance's intended use Chemical production, analytical chemistry, laboratory synthesis, industrial applications. Substance uses advised against The product should not be used in ways other then those referred in Section 1. Chemical safety report 1.3. Details of the supplier of the safety data sheet Supplier Name or trade name Ing. Petr Švec - PENTA s.r.o. Address Radiová 1122/1, Praha 10, 102 00 Czech Republic Identification number (CRN) 02096013 VAT Reg No CZ02096013 Phone +420 226 060 681 E-mail [email protected] Web address www.pentachemicals.eu Competent person responsible for the safety data sheet Name Ing. Petr Švec - PENTA s.r.o. E-mail [email protected] 1.4. Emergency telephone number National Health Service (NHS) 111 National poisoning information centre Scotland, NHS 24: 111 SECTION 2: Hazards identification 2.1. Classification of the substance or mixture Classification of the substance in accordance with Regulation (EC) No 1272/2008 The substance is classified as dangerous. Acute Tox. 4, H302 Eye Dam. 1, H318 Aquatic Acute 1, H400 Aquatic Chronic 1, H410 Full text of all classifications and hazard statements is given in the section 16.
    [Show full text]